AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02404701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
Study NCT02404701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea extract
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
Study NCT02404701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bilberry
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
Study NCT02404701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
Study NCT04289948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phage
Description: The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
Study NCT04289948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phage
Description: The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
Study NCT02818803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis
Study NCT02818803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole
Study NCT02472093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercises treatment
Description: Includes different types of exercises: low-impact to moderate aerobic training; walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing. The heart rate was monitored through the use of a heart rate monitor, which allowed not to exceed the threshold.
Study NCT02472093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perceptive Rehabilitation Treatment
Description: therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips.
Study NCT02404701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk thistle
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
Study NCT02404701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
Study NCT02404701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe vera
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
Study NCT01415232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonosite S-Nerve® US system (SonoSite, Bothell,WA)
Description: Ultrasound to measure depth to the epidural space in morbidly obese parturients
Study NCT00698256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vegetable oil-based spread and oat-based drink (no brand name available)
Description: spread and drink (9 g stanols/d)
Study NCT00698256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vegetable oil-based spread and oat-based drink (no brand name available)
Description: Spread and drink (not containing added stanols)
Study NCT00828698 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00522262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Description: Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
Study NCT04433611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Description: intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy~The VAS consisted of a 10 cm line ranging from 0 to 10 (anchored by 0=no pain and 10=very severe pain). Patients were asked to mark the number that represented their perceived level of pain. Based on the VAS scores, the pain level ratings were classified as: mild (rated 1-3), moderate (4-6) or severe (7-10).
Study NCT04433611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % normal saline
Description: intrauterine infusion of 0.9 % normal saline
Study NCT02246166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test tablet
Description: The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
Study NCT02246166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
Study NCT01879345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 - 1800 mg (Group 1)
Description: 3 tablets of BIA 2-093
Study NCT01879345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 - 2400 mg (Group 2)
Description: 4 tablets of BIA 2-093 600 mg
Study NCT01879345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets
Study NCT02294786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
Study NCT04222985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 6
Description: Route of administration: Intramuscular
Study NCT04222985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular
Study NCT04222985 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular
Study NCT02294786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
Study NCT02294786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
Study NCT03820310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous Tcm cellular immunotherapy
Description: autologous cellular immunotherapy plus traditional therapy. • cells will be infused in 3-5×109 cells/100 ml 1 month after radical resection, then cells will be infused as the same dose followed by a 1 month rest period, Each subject in experimental group will receive a total of 5 cell infusions.
Study NCT04459260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: A standardized evidence-based treatment manual based on cognitive behavior therapy, developed specifically for targeting perfectionism (Egan et al., 2016). Includes the following components: 1) providing psychoeducation about perfectionism and creating an individualized conceptualization 2) broadening the domains for self-evaluation 3) testing out beliefs and predictions, and 4) addressing personal standards and self-criticism.~Week 1: Understanding your perfectionism.~Week 2: Your own model, values, and motivation.~Week 3: Surveys and experiments.~Week 4: Dealing with perfectionistic behaviors.~Week 5: New ways of thinking.~Week 6: Self-criticism and self-compassion.~Week 7: Self-worth.~Week 8: Maintain and continue positive change.
Study NCT04459260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol
Description: A standardized evidence-based treatment manual based on cognitive behavior therapy, developed to target the shared emotional factors in depression and anxiety disorders (Ellard et al., 2010). Fundamental to this approach is to register and become more aware of the emotions, cognitions, and physical sensations that occur in difficult situation, and to try out more adaptive ways of coping in these instances.~Week 1: Emotional symptoms.~Week 2: Understanding your emotions.~Week 3: Emotional awareness.~Week 4: Thoughts.~Week 5: Behaviors.~Week 6: Emotional exposure.~Week 7: Continued emotional exposure.~Week 8: Planning ahead.
Study NCT00953498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: After randomization, patients will be treated by pioglitazone or rosiglitazone
Study NCT00953498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: treatment with rosiglitazone at a dose between 4mg and 8 mg/day
Study NCT03332485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECP Colon Prep Kit
Description: ECP Colon Prep Kit
Study NCT01989663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% vaginally applied tenofovir gel
Study NCT01989663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir film- 10mg
Study NCT01989663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Film-40 mg
Study NCT01989663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo Gel
Study NCT01989663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Film
Study NCT01588821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg daily by mouth
Study NCT02472093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group did brief educational sessions.
Study NCT02319356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: (BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
Study NCT02319356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beetroot juice
Description: (PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
Study NCT01744561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
Study NCT03204344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate (Outfast)
Description: For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above.
Study NCT03204344 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine fasting
Description: For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary.
Study NCT03112811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Description: The manual technique of the chest physiotherapy to move the secretions
Study NCT03112811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation
Description: The instrumental technique of the chest physiotherapy to move the secretions
Study NCT03735940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spot monitoring device, excl. Sham
Description: o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
Study NCT03932240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate (FC)
Description: The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
Study NCT03932240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
Study NCT02246361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Information Leaflet (PIL)
Description: Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
Study NCT04154098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scapula orthosis assistance
Description: Participants are elevating their arm while their scapula is assisted by the scapula orthosis
Study NCT03332485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep®
Description: MoviPrep®
Study NCT01987531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: left ventricular epicardial pacing lead
Study NCT03737851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elezanumab
Description: solution for infusion
Study NCT04362020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distal radial access
Description: Distal radial access and No anticoagulation
Study NCT04362020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distal radial access
Description: Distal radial access and ACT-guided anticoagulation
Study NCT00704821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: Oral
Study NCT00704821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous infusion
Study NCT01638520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pascolizumab
Description: 0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
Study NCT01638520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline (volume determined based on weight of patient, and cohort of enrollment)
Study NCT04353063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care with a personalized care
Description: During the 4-week intervention, participants will be given stickers by the research assistant to increase their motivation to walk. A sticker will be given once a participant reaches a daily walking-time goal. The number of stickers participants receive depends on the number of days they reach their daily goals. The stickers can be redeemed for the participant's choice of gift in the gift shelf of the ward or on a gift card. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4